Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

common-default.jpeg

Terms / Notices

Cookies

Privacy Policy

Reporting Hotline

Attorney Advertising

Alumni

  Linkedin

MoFo LinkedIN

  Facebook

MoFo Facebook

YouTube

MoFo Youtube

Morrison Foerster - Footer

BIOHK2022: Trends, Opportunities, and Outlook for Biotech Investment

You have not solved the recaptcha challenge yet or session expired, try again.

Email Disclaimer

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

On December 16, 2022, MoFo Partner and Co-Chair of Asia Private Equity practice, Thomas Chou, will speak at the panel “Trends, Opportunities, and Outlook for Biotech Investment” at BIOHK2022, an international convention organized by Hong Kong Biotechnology Organization to introduce novel state of-the-art biotech innovations from around the globe.

On December 16, 2022, MoFo Partner and Co-Chair of Asia Private Equity practice, Thomas Chou, will speak at the panel “Trends, Opportunities, and Outlook for Biotech Investment” at BIOHK2022, an international convention organized by Hong Kong Biotechnology Organization to introduce novel state‑of-the-art biotech innovations from around the globe.Moderated by Philip Law, Venture Capital & Private Equity Partner of Deloitte China, this panel will examine key trends, opportunities, and outlook for biotech investment in North Asia / China and Hong Kong. The topics will include:<ul><li>Observations of the global investment market and its latest developments.</li><li>Differences between China, Europe, and U.S. investment trends and prospects.</li><li>The driving growth and unique opportunities in China's Biotech industry.</li><li>How does venture capital investing contribute to grooming young Biotech companies? What types of Biotech companies are attracting VC investment?</li><li>What can Hong Kong do additionally to become the best Global Investment Hub?</li></ul>Other panelists include:<ul><li>Simone Song, Founder and Senior Partner, ORI Capital;</li><li>Dr. Maggie Lo, Deputy Head Innovation and Technology, Invest Hong Kong; and</li><li>Samuel Siu, Senior Executive Director, Morgan Stanley.</li></ul><a href="https://www.bio-hk.com/" target="_blank">View more information</a> and <a href="https://www.bio-hk.com/registration-form/" target="_blank">register</a>.<hr>

Sign Up

Thomas has devoted more than a quarter century to advising sophisticated and impactful clients to complete complex, market-leading transactions globally, with deep experience in the U.S. and Asia Pacific region. He concentrates his practice on cross-border mergers and acquisitions, joint ventures, and emerging company and venture capital advisory and transactional work. Thomas’ clients include industry-leading emerging growth companies and a broad range of investors who fund them (traditional private equity and venture capital funds, prominent Asian family offices, the corporate/strategic investment arms of large corporates, insurance companies, and sovereign wealth funds). His broad industry coverage includes biopharma, MedTech and digital health; mobile, gaming, and entertainment; material science and semiconductors (equipment and design); Deeptech/AI; Fintech (payments, remittances, and digital assets); PropTech; FoodTech; health and wellness; and consumer products and retail.Clients and outside ranking organizations routinely cite Thomas’ accomplishments:<ul><li>Thomas is “a strong advocate for his client, offering strategic and actionable advice, evaluating and clearly prioritizing the key issues in complex situations and proactively anticipating concerns from counterparties in negotiations."</li><li>“Thomas Chou is excellent in understanding the industry and leads the team in working on the same. He is very responsive and works 24 hours responding to the clients.”</li><li>“Thomas has significant experience handling complex cross–border transactions across the Asia–Pacific region. His counsel is frequently sought by global technology corporations to advise on their investments in the region. He also commands considerable respect from private equity clients.”</li><li>His clients pinpoint his “decades of venture capital experience both in the United States and in Asia,” with one noting: “He is patient, attentive to details and someone who has clearly conquered many battlefields.”</li><li>Thomas is particularly praised for his communications skills, with clients saying, “Any issues we had he would always provide a solution. He is not only interpreting regulations, but he is also commercially savvy.”</li></ul>At MoFo, Thomas is an active member of our Emerging Company + Venture Capital, Private Equity, and M&A practices, all of which are consistently highly ranked in major independent industry league tables and lawyer ranking organizations.Thomas is also a proud member of the board of directors of the Starlight Children’s Foundation.

周至恒（Thomas Chou）律师在公司业务领域非常活跃，重点处理跨境并购（中国境内外）、合资、私募股权和风险资本融资业务。他的客户包括新兴成长型公司，传统以及非传统投资者（私募股权和风险投资基金，家族办公室，公司/公司的战略投资部门，金融机构以及主权财富基金）。他的执业领域主要是技术、媒体和电信、医疗和生命科学以及消费和零售业。客户和外部评级机构都经常称赞周律师的成就：<ul><li>“周律师在处理亚太地区复杂跨境交易方面经验丰富，全球科技公司常因在该地区的投资而寻求其意见，他也广受私募股权客户推崇。”</li><li>“（周律师）资历深厚，精于各种风险投资及私募股权事宜，包括前期与后期的投资及并购，他在科技领域的经验尤其丰富。”</li><li>客户赞赏他“在美国及亚洲均有数十年风险投资经验”，并称其“非常耐心，注重细节，实战经验丰富”。</li><li>周律师的沟通技巧尤其为人所称道，他的客户指出：“不管我们出现任何问题，周律师都能提出解决方案。他不仅能准确把握法律条文，同时极具商业头脑。”</li></ul>周律师是美富亚洲私募股权业务的联席主管，也是新兴公司 + 风险投资业务组和并购业务组的活跃成员。他在上述业务领域均持续受到独立的法律行业排行榜和律师评级机构的高度认可。周律师还是星光儿童基金会的董事会成员。

BIOHK2022: Trends, Opportunities, and Outlook for Biotech Investment

16 Dec 2022 11:20 AM - 11:55 AM HKT